The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation exactly as intended across more than 6,300 high-risk patients. It produced no reduction in the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke. The hazard ratio was 0.99, with a 95% confidence interval of 0.88 to 1.11. The drug engaged its biological target and missed its clinical one.
That gap between mechanism and outcome is what makes the result significant well beyond a single company’s pipeline. For nearly a decade, cardiologists have treated vascular inflammation as one of the most promising remaining targets in atherosclerosis. The ziltivekimab ZEUS trial was the largest and most direct test of that idea yet attempted, and it came back flat.
What the ZEUS trial set out to test
Ziltivekimab is a fully human monoclonal antibody directed against the interleukin-6 ligand, a pro-inflammatory cytokine that sits centrally in the signalling cascade linking inflammation to atherothrombosis. Novo Nordisk acquired the asset through its 2020 purchase of Corvidia Therapeutics. It paid 725 million US dollars upfront, with total payments of up to 2.1 billion dollars on achievement of regulatory and sales milestones.
The trial, registered as NCT05021835, was a multinational, double-blind, placebo-controlled and event-driven study. It randomised 6,376 participants in a 1:1 ratio. Each received either ziltivekimab 15 mg subcutaneously once monthly or matching placebo, added to standard of care. Eligibility required established atherosclerotic cardiovascular disease, chronic kidney disease, and a high-sensitivity C-reactive protein level of at least 2 mg/L.
The enrolled population was deliberately high risk. At randomisation, mean age was 69.5 years and 27.5% of participants were female. Hypertension was present in 92.0%, diabetes in 65.7% and heart failure in 41.3%. Mean estimated glomerular filtration rate was 44.5 mL/min/1.73 m2, median hsCRP was 4.5 mg/L and median IL-6 was 4.9 pg/mL. The primary endpoint was time to first occurrence of three-point major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.
What the data showed
Ziltivekimab reduced free IL-6 and hsCRP by the margins the programme had anticipated, confirming that the antibody reached and inhibited its target. That pharmacological success did not carry through to the endpoint that mattered. The hazard ratio of 0.99 sits almost exactly on the line of no effect. The confidence interval of 0.88 to 1.11 excludes the scale of benefit investigators had hoped for.
On safety, Novo Nordisk reported that overall rates of adverse events and serious adverse events were broadly comparable between arms. A higher proportion of participants receiving ziltivekimab experienced serious infections, a finding the company described as consistent with IL-6 pathway inhibition. No difference in all-cause mortality was observed between the two groups.
“ZEUS was designed to test whether inhibition of the IL-6 pathway could translate reductions in cardiovascular inflammation into fewer major cardiovascular events. Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population,” Martin Holst Lange, executive vice president, chief scientific officer and head of research and development at Novo Nordisk, said in the company’s announcement.
Lange added that the outcome does not alter the company’s strategic commitment to cardiovascular disease. He said the study yields evidence that will inform ongoing research.
The paradox of a drug that worked but did not help
The scientific interest here lies in the dissociation between biomarker and outcome. Reductions in hsCRP and IL-6 have functioned for years as a working proxy for cardiovascular benefit. The reasoning was that lower inflammatory signalling should mean fewer plaque ruptures and thrombotic events. The ziltivekimab ZEUS trial tested that chain of inference directly, in a population selected precisely because its inflammatory burden was elevated, and the chain broke.
Several explanations remain open. IL-6 may be a marker of vascular risk rather than a driver of it in this particular population. The residual risk in patients with advanced chronic kidney disease may be dominated by mechanisms that anti-inflammatory therapy cannot reach. It is also possible that the degree or duration of inhibition achieved was insufficient, or that the wrong step in the inflammatory cascade was targeted. Full results, due to be presented at a scientific meeting later in 2026, should narrow that list considerably.
Why the ziltivekimab ZEUS trial matters beyond Novo Nordisk
The inflammatory hypothesis of atherosclerosis has accumulated a mixed evidence base. The CANTOS trial provided its first clinical validation in 2017. Canakinumab, an interleukin-1 beta inhibitor, produced a 15% reduction in major adverse cardiovascular events among post-infarction patients with elevated hsCRP at the 150 mg dose, the only dose to meet the trial’s multiplicity-adjusted threshold for significance. The hazard ratio was 0.85, with a confidence interval of 0.74 to 0.98. Canakinumab was never approved for cardiovascular use, amid concerns about infection risk and cost. The subsequent CIRT trial of low-dose methotrexate was stopped for futility.
Low-dose colchicine has fared better. COLCOT reported a 23% relative risk reduction in major vascular events after recent acute coronary syndrome, and LoDoCo2 reported a 31% reduction in stable coronary disease. On that evidence, the US Food and Drug Administration approved colchicine 0.5 mg daily in June 2023 as the first anti-inflammatory therapy indicated for reducing cardiovascular events. Even here the picture is uneven, since the CLEAR SYNERGY trial in patients treated with PCI after acute myocardial infarction, predominantly ST-elevation, returned a neutral result.
ZEUS therefore did not fail against a settled consensus. It tested the downstream IL-6 step in a pathway where the upstream IL-1 beta step had shown a modest signal, and it found nothing. The market reaction suggested investors read the ziltivekimab result as a class problem rather than a molecule problem. BioAge Labs, whose lead asset BGE-102 is an oral NLRP3 inhibitor in mid-stage cardiovascular testing, closed down 63.6% at 9.04 dollars a share on the day of the announcement. Monte Rosa Therapeutics, which is advancing a molecular glue degrader aimed at IL-1 beta and NLRP3-driven inflammation, fell 27% to 16.52 dollars. The result landed in a week of otherwise mixed late-stage clinical trial readouts across the sector.
What happens to ziltivekimab next
Two further cardiovascular outcomes trials continue. HERMES is testing ziltivekimab in roughly 4,900 patients with heart failure with preserved or mildly reduced ejection fraction. ARTEMIS is studying patients following an acute myocardial infarction. Both are expected to report in the first half of 2027. ARTEMIS is the largest of the three at roughly 8,500 participants. Across all three studies, the programme has enrolled close to 20,000 people.
Those trials address different populations and different clinical questions, so ZEUS does not determine their outcomes. Heart failure with preserved ejection fraction, in particular, has a distinct inflammatory biology from atherosclerotic event prevention. Confidence in the mechanism has nonetheless been weakened, and the burden of proof on the remaining readouts is now considerably heavier.
What it means for Novo Nordisk
The commercial reading was immediate. Copenhagen-listed Novo Nordisk shares fell as much as 10% on the day of the announcement, and the US-listed stock closed roughly 9% lower. The company has spent 2026 attempting to demonstrate that it can grow beyond Wegovy and Ozempic, and ziltivekimab had been positioned as the clearest evidence for that case. The ziltivekimab ZEUS trial was the first of its three late-stage cardiovascular readouts to report. Analysts had widely expected at least some cardiovascular benefit.
Novo Nordisk said the result will trigger a non-cash impairment charge in the third quarter of 2026. Its previously communicated adjusted operating profit outlook for the year is unchanged. The financial consequence is therefore contained. The strategic one is less so, since the pipeline argument for diversification beyond incretins now rests more heavily on assets that have yet to report.
For the wider field, the useful framing is not that inflammation has been ruled out as a cardiovascular target. It is that the relationship between inflammatory biomarkers and clinical events is looser than a decade of surrogate-driven reasoning had assumed. HERMES and ARTEMIS will test whether that looseness is universal or specific to the population the ziltivekimab ZEUS trial selected.
